Dew (or anyone else knowledgeable), given the current healthcare legislation that is now law, is there clarity regarding biosimilar, biobetter generic drug production? If not, could the FDA delay re MNTA be related to some need for legislative guidance for the agency? Thanks bp
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.